OPSENS ANNOUNCES FDA CLEARANCE FOR THE SAVVYWIRE(TM) FOR USE IN TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR) PROCEDURES

Stock Information for Opsens Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Opsens Inc

HAEMONETICS COMPLETES ACQUISITION OF OPSENS
OPSENS RECEIVES FINAL ORDER FOR ARRANGEMENT WITH HAEMONETICS
OPSENS' SHAREHOLDERS APPROVE ARRANGEMENT WITH HAEMONETICS
OPSENS OBTAINS REGULATORY CLEARANCE OF ARRANGEMENT IN THE UNITED STATES AND CANADA; REGULATORY APPROVALS CONDITION SATISFIED
OPSENS ANNOUNCES FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS
INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS SHAREHOLDERS VOTE "FOR" OPSENS INC. PLAN OF ARRANGEMENT WITH HAEMONETICS CORPORATION
OPSENS RECEIVES INTERIM ORDER AND FILES MANAGEMENT INFORMATION CIRCULAR IN CONNECTION WITH SPECIAL MEETING OF SHAREHOLDERS
OPSENS ANNOUNCES THE POSITIVE CLINICAL RESULTS FROM THE SAFE-TAVI STUDY WITH SAVVYWIRE IN EUROPE

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.